… Warfarin sodium remains an effective option for treating venous thromboembolism (VTE)
despite a narrow therapeutic index, wide inter-patient dosing variability, predisposition to drug …

… to warfarin use and monitoring, or the effects of warfarin discontinuation on risk of venous
thromboembolism (… This study investigated the effect of warfarin discontinuation on rates of VTE …

… They occurred in 11 of 12 warfarin patients when the INR was within (7) or above (4) the
therapeutic range. The median time in therapeutic range for the warfarin patients with recurrent …

… patients with acute venous thromboembolism, we compared 6 months of treatment with
dabigatran, administered at a dose of 150 mg twice daily, with warfarin … warfarin (when warfarin is …

… (AF) and treatment and secondary prevention of venous thromboembolism (VTE). In 2004,
more than 30 million prescriptions for warfarin, the most common vitamin K antagonist, were …

… randomly assigned patients with acute venous thromboembolism, who … patients with
creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin…

… venous thromboembolism. The similar efficacies of dabigatran and standard treatment with
warfarin … with the new anticoagulants in venous thromboembolism or in atrial fibrillation, there …

… Patients with idiopathic venous thromboembolism who had received full-dose … intensity
warfarin (target INR, 1.5 to 2.0). Participants were followed for recurrent venous thromboembolism…

… blind study in patients with unprovoked venous thromboembolism in which we compared
warfarin therapy with a target INR of 1.5 to 1.9 (low-intensity therapy) with warfarin therapy with …

… to show that dabigatran is noninferior to warfarin in preventing recurrent venous
thromboembolism (including death related to venous thromboembolism). The sample size was …